Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma [clinicaltrials:NCT00003954]

Bio2RDF uri

Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma [clinicaltrials:NCT00003954]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00003954

Bio2RDF identifier

NCT00003954

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00003954

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

In this study donor bon ...... he benefits of this procedure

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Melphalan and Stem Cell Transp ...... h Stage I-III Multiple Myeloma

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

PFS From the date of transplant until the time of progression, relapse, death, or the date the patient was last known to be in remission, up to 3 years [clinicaltrials_resource:32bf3bae5268ff5f506fc94b60c859d8]

PFS From the date of transplant until the time of progression, relapse, death, or the date the patient was last known to be in remission, up to 3 years [clinicaltrials_resource:a198afbb05694d7d107322ec4c60772f]

PFS From the date of transplant until the time of progression, relapse, death, or the date the patient was last known to be in remission, up to 3 years [clinicaltrials_resource:ad3fae6579be00b5d07fb3feb52bdd7e]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

PFS From the date of transplant until the time of progression, relapse, death, or the date the patient was last known to be in remission, up to 3 years [clinicaltrials_resource:0c27f75e36013adab911c531ae8a6d90]

PFS From the date of transplant until the time of progression, relapse, death, or the date the patient was last known to be in remission, up to 3 years [clinicaltrials_resource:2d1a7a763cf2d972041d2c4aff16f81d]

PFS From the date of transplant until the time of progression, relapse, death, or the date the patient was last known to be in remission, up to 3 years [clinicaltrials_resource:6b9ae406f5aef9d422eb53b6d39805a6]

PFS From the date of transplant until the time of progression, relapse, death, or the date the patient was last known to be in remission, up to 3 years [clinicaltrials_resource:7899ea20735f21931ff615e6f7655f11]

collaborator [clinicaltrials_vocabulary:collaborator]

Fred Hutchinson Cancer Research Center [clinicaltrials_resource:0413b67bb11aa7435c2cb6e1a4385dec]

condition [clinicaltrials_vocabulary:condition]

Stage II Multiple Myeloma [clinicaltrials_resource:047fb10a68a16ec55aae05b01b534fa5]

Stage I Multiple Myeloma [clinicaltrials_resource:09aa918101e9b2eb2be0e2b896bbc601]

Refractory Multiple Myeloma [clinicaltrials_resource:5a3d33eaa4cadc318c46b13378fbc251]

Stage III Multiple Myeloma [clinicaltrials_resource:a4dfb70a03fd8dd682db7b84edc1ae9f]

condition browse [clinicaltrials_vocabulary:condition-browse]

Neoplasms, Plasma Cell [clinicaltrials_resource:aa41b92d39b7feaa4386ec3c5f5bf8bf]

Multiple Myeloma [clinicaltrials_resource:b494bb98e15106ec59d72f9432b560bf]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Neoplasms, Plasma Cell [clinicaltrials_resource:aa41b92d39b7feaa4386ec3c5f5bf8bf]

Multiple Myeloma [clinicaltrials_resource:b494bb98e15106ec59d72f9432b560bf]

country [clinicaltrials_vocabulary:country]

United States [clinicaltrials_resource:f253efe302d32ab264a76e0ce65be769]

detailed description [clinicaltrials_vocabulary:detailed-description]

PRIMARY OBJECTIVES: ...... are followed up for 3 years.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00003954 [clinicaltrials_resource:cda51d2e68c4f7d4de7cf4792241f558]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

1999-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

total-body irradiation [clinicaltrials_resource:08101c0122d0f82d8b63575bf754646d]

mycophenolate mofetil [clinicaltrials_resource:2ae48f6b1f72c973b2cf0680d34da069]

cyclosporine [clinicaltrials_resource:40e10fb5aba8df0576cd8be734452ee8]

autologous bone marrow transplantation [clinicaltrials_resource:5330391c95a40091a15d378c64db8dc4]

autologous hematopoietic stem cell transplantation [clinicaltrials_resource:6435f5a4b65c2de06cf80804067b7ccc]

therapeutic allogeneic lymphocytes [clinicaltrials_resource:7620dcd5856f868a36fc7ef7c87a9bf9]

peripheral blood stem cell transplantation [clinicaltrials_resource:a98c07a9b7be398075354b475f69138f]

peripheral blood stem cell transplantation [clinicaltrials_resource:daf6cfc6c49e73f4a8cdffcdcdbcc1e7]

melphalan [clinicaltrials_resource:e22ed3220cf4693348d699a5f240ae64]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Mycophenolate mofetil [clinicaltrials_resource:31de209b7264303fdda3c8b57bf0b039]

Cyclosporins [clinicaltrials_resource:a78396bd0ab3d3f25852a0d4008cbdf4]

Cyclosporine [clinicaltrials_resource:d5ad0819e34429f7e4abc786a3f5366c]

Melphalan [clinicaltrials_resource:e704a7a0fbac5474112d592ea9773b11]

Mycophenolic Acid [clinicaltrials_resource:f75b029fbf569731a07aa713250d93da]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Fred Hutchinson Cancer Research Center [clinicaltrials_resource:0413b67bb11aa7435c2cb6e1a4385dec]

location [clinicaltrials_vocabulary:location]

City of Hope [clinicaltrials_resource:995f8cbf9660636db8d83e8287dd45a6]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00003954

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Allogeneic Stem Cell Transplan ...... llografting After Low Dose TBI

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

1,383e+3

http://www.w3.org/2001/XMLSchema#float

overall official [clinicaltrials_vocabulary:overall-official]

David Maloney [clinicaltrials_resource:1f0e2606ce0f9eaea2a6f87938afe46a]

overall status [clinicaltrials_vocabulary:overall-status]

Active, not recruiting [clinicaltrials_resource:a6bc1606956390bcd6a391faced78809]

oversight [clinicaltrials_vocabulary:oversight]

United States: Federal Government [clinicaltrials_resource:15a952dd0198445f4ddd5909936bc0e7]

phase [clinicaltrials_vocabulary:phase]

Phase 1/Phase 2 [clinicaltrials_resource:72d8d9eabd48f679d5dffa41c4dd93f7]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2002-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

NCI-2012-00670

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Fred Hutchinson Cancer Research Center [clinicaltrials_resource:0413b67bb11aa7435c2cb6e1a4385dec]

start date [clinicaltrials_vocabulary:start-date]

1999-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00003954 study design [clinicaltrials_resource:9f018fed0fa10e47f46e2e6f27562640]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00003954

verification date [clinicaltrials_vocabulary:verification-date]

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00003954

http://www.w3.org/2001/XMLSchema#string

title

Melphalan and Stem Cell Transp ...... h Stage I-III Multiple Myeloma

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Melphalan and Stem Cell Transp ...... a [clinicaltrials:NCT00003954]

@en